Anticoagulation Management for AF Cardioversion — free guideline decision tool
This tool gives the peri-cardioversion anticoagulation strategy for atrial fibrillation by AF duration and hemodynamic stability.
Open guideline tool →Guideline-based
Implements the decision logic from published clinical guidelines.
Runs in your browser
No installation. Enter the patient's values and get a guideline recommendation instantly.
Data stays local
Nothing is uploaded. Results are for licensed clinicians only.
Worked calculation
The values below come from this tool's own example placeholders and are computed server-side with the formula shown on this page, so the arithmetic can be checked quickly. It demonstrates how to substitute values only — it is not clinical advice and not a real case.
| AF duration | < 48 hours (definite) |
|---|---|
| Hemodynamically unstable | No |
→Pre-cardioversion anticoagulation strategy< 48 h: anticoagulate at presentation, low-risk may cardiovert directly
- Peri-cardioversion：Duration < 48 h: start anticoagulation at presentation (parenteral anticoagulation or NOAC); low thromboembolic risk may be cardioverted directly (high stroke risk should be treated as ≥ 48 h). Continue anticoagulation at least 4 weeks after cardioversion
- After cardioversion：Regardless of sinus-rhythm maintenance or stroke risk, anticoagulate at least 4 weeks after cardioversion (thrombus risk during atrial stunning)
- Long-term anticoagulation：Whether to anticoagulate long-term is decided by CHA₂DS₂-VASc stroke risk (see AF anticoagulation tool), not by whether cardioversion was done or sinus rhythm achieved
| AF duration | ≥ 48 hours or unknown duration |
|---|---|
| Hemodynamically unstable | Yes |
→StrategyImmediate cardioversion (no delay)
- Cardioversion：Hemodynamically unstable (hypotension/myocardial ischemia/acute HF/shock): immediate synchronized cardioversion, not delayed for anticoagulation
- Anticoagulation：Start anticoagulation as soon as possible (UFH/LMWH or NOAC); continue at least 4 weeks after cardioversion
- Long-term：Then decide long-term anticoagulation by CHA₂DS₂-VASc (see AF anticoagulation tool)
Common questions
What is Anticoagulation Management for AF Cardioversion?
This tool gives the peri-cardioversion anticoagulation strategy for atrial fibrillation by AF duration and hemodynamic stability.
How is Anticoagulation Management for AF Cardioversion calculated? What is the core formula?
Unstable → immediate cardioversion, anticoagulate ASAP. < 48 h → anticoagulate at presentation, low-risk may cardiovert directly. ≥ 48 h/unknown → anticoagulate ≥ 3 weeks or TEE-exclude thrombus. All → ≥ 4 weeks after cardioversion.
When is Anticoagulation Management for AF Cardioversion used?
Use to decide pre-cardioversion anticoagulation (or TEE) and the mandatory post-cardioversion course, separating unstable patients who need immediate cardioversion.
What are the key clinical points for Anticoagulation Management for AF Cardioversion?
Anticoagulation continues at least 4 weeks after cardioversion regardless of duration or stroke risk, because of thrombus risk during atrial stunning. (original synthesis · not guideline verbatim) Long-term anticoagulation is decided by CHA₂DS₂-VASc, not by whether sinus rhythm was achieved. A left-atrial-appendage thrombus on TEE defers cardioversion for 4–12 weeks of anticoagulation.
What are the limits and cautions when using Anticoagulation Management for AF Cardioversion?
For licensed clinicians and clinical researchers. Interpret results with history, investigations and local protocols; not a diagnosis or prescription, and not a substitute for multidisciplinary decision-making or local guidelines.
How is Anticoagulation Management for AF Cardioversion calculated in practice? Can you show a worked example?
Inputs: AF duration < 48 hours (definite), Hemodynamically unstable No → Result: Pre-cardioversion anticoagulation strategy < 48 h: anticoagulate at presentation, low-risk may cardiovert directly（Peri-cardioversion: Duration < 48 h: start anticoagulation at presentation (parenteral anticoagulation or NOAC); low thromboembolic risk may be cardioverted directly (high stroke risk should be treated as ≥ 48 h). Continue anticoagulation at least 4 weeks after cardioversion, After cardioversion: Regardless of sinus-rhythm maintenance or stroke risk, anticoagulate at least 4 weeks after cardioversion (thrombus risk during atrial stunning), Long-term anticoagulation: Whether to anticoagulate long-term is decided by CHA₂DS₂-VASc stroke risk (see AF anticoagulation tool), not by whether cardioversion was done or sinus rhythm achieved） Inputs: AF duration ≥ 48 hours or unknown duration, Hemodynamically unstable Yes → Result: Strategy Immediate cardioversion (no delay)（Cardioversion: Hemodynamically unstable (hypotension/myocardial ischemia/acute HF/shock): immediate synchronized cardioversion, not delayed for anticoagulation, Anticoagulation: Start anticoagulation as soon as possible (UFH/LMWH or NOAC); continue at least 4 weeks after cardioversion, Long-term: Then decide long-term anticoagulation by CHA₂DS₂-VASc (see AF anticoagulation tool)）
Run Anticoagulation Management for AF Cardioversion now
This tool gives the peri-cardioversion anticoagulation strategy for atrial fibrillation by AF duration and hemodynamic stability.
Open guideline tool →For licensed clinicians. Not a substitute for clinical judgement.
Paste the link in Slack, Teams, X, or LinkedIn — the preview image comes from this page’s Open Graph card.